Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径

2018-11-26 美国心脏病学会 J Am Coll Cardiol.November 2018.

2型糖尿病及粥样硬化性心血管疾病心血管风险新型治疗

2018年11月，美国心脏病学会(ACC)发布了降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径共识，旨在教育心脏病学家使用两种主要的新型糖尿病药物：钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽1受体激动剂（GLP-1RA），这两种药物均被证实可降低伴心血管疾病和糖尿病患者的不良结局风险。

中文标题：

2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径

英文标题：

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

发布机构：

美国心脏病学会

发布日期：

2018-11-26

简要介绍：

2018年11月，美国心脏病学会(ACC)发布了降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径共识，旨在教育心脏病学家使用两种主要的新型糖尿病药物：钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽1受体激动剂（GLP-1RA），这两种药物均被证实可降低伴心血管疾病和糖尿病患者的不良结局风险。 

拓展指南：与糖尿病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径)] GetToolGuiderByIdResponse(projectId=1, id=d76de1c0016e0058, title=2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径, enTitle=2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease, guiderFrom=J Am Coll Cardiol.November 2018., authorId=null, author=, summary=2018年11月，美国心脏病学会(ACC)发布了降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径共识，旨在教育心脏病学家使用两种主要的新型糖尿病药物：钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽1受体激动剂（GLP-1RA），这两种药物均被证实可降低伴心血管疾病和糖尿病患者的不良结局风险。 , cover=, journalId=null, articlesId=null, associationId=849, associationName=美国心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Nov 26 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年11月，美国心脏病学会(ACC)发布了降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径共识，旨在教育心脏病学家使用两种主要的新型糖尿病药物：钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽1受体激动剂（GLP-1RA），这两种药物均被证实可降低伴心血管疾病和糖尿病患者的不良结局风险。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>糖尿病</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=03e111c00166a8f0" title="2018 ADA立场声明：青年起病的2型糖尿病的评估和管理" target=_blank>2018 ADA立场声明：青年起病的2型糖尿病的评估和管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=f6de81c001652237" title="2018 丹麦循证指南：糖尿病视网膜病变的筛查" target=_blank>2018 丹麦循证指南：糖尿病视网膜病变的筛查</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=652da1c0016a8946" title="2018 ADA/EASD共识：2型糖尿病患者高血糖的管理" target=_blank>2018 ADA/EASD共识：2型糖尿病患者高血糖的管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=199a01c0016a33c4" title="2018 ISPAD临床实践指南：儿童青少年单基因糖尿病的诊断和管理" target=_blank>2018 ISPAD临床实践指南：儿童青少年单基因糖尿病的诊断和管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=b97101c0016a29a6" title="2018 ISPAD临床实践指南：儿童青少年糖尿病的定义，流行病学和分类" target=_blank>2018 ISPAD临床实践指南：儿童青少年糖尿病的定义，流行病学和分类</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病), TagDto(tagId=83672, tagName=及粥样硬化性心血管疾病), TagDto(tagId=1567, tagName=心血管风险), TagDto(tagId=26552, tagName=新型治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10740, appHits=557, showAppHits=0, pcHits=8166, showPcHits=2623, likes=263, shares=18, comments=7, approvalStatus=1, publishedTime=Fri Nov 30 13:08:11 CST 2018, publishedTimeString=2018-11-26, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Nov 30 13:08:11 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 04:17:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径)])
2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=964008, encodeId=3efd9640082b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=彧日东升, createdTime=Sun May 09 16:54:32 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355407, encodeId=4e2d35540e08, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Fri Dec 14 18:46:09 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354960, encodeId=712c35496094, content=学习了，嘻嘻，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/07/f34da8a238e598ec20667d5040f7d424.jpg, createdBy=ae7e2163267, createdName=Youngsing, createdTime=Sun Dec 09 22:18:30 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354498, encodeId=24b135449808, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Wed Dec 05 08:16:56 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354426, encodeId=b8e63544262b, content=有翻译版的吗？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Tue Dec 04 12:44:20 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2021-05-09 彧日东升

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=964008, encodeId=3efd9640082b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=彧日东升, createdTime=Sun May 09 16:54:32 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355407, encodeId=4e2d35540e08, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Fri Dec 14 18:46:09 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354960, encodeId=712c35496094, content=学习了，嘻嘻，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/07/f34da8a238e598ec20667d5040f7d424.jpg, createdBy=ae7e2163267, createdName=Youngsing, createdTime=Sun Dec 09 22:18:30 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354498, encodeId=24b135449808, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Wed Dec 05 08:16:56 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354426, encodeId=b8e63544262b, content=有翻译版的吗？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Tue Dec 04 12:44:20 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2018-12-14 12478b7dm11(暂无昵称)

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=964008, encodeId=3efd9640082b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=彧日东升, createdTime=Sun May 09 16:54:32 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355407, encodeId=4e2d35540e08, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Fri Dec 14 18:46:09 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354960, encodeId=712c35496094, content=学习了，嘻嘻，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/07/f34da8a238e598ec20667d5040f7d424.jpg, createdBy=ae7e2163267, createdName=Youngsing, createdTime=Sun Dec 09 22:18:30 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354498, encodeId=24b135449808, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Wed Dec 05 08:16:56 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354426, encodeId=b8e63544262b, content=有翻译版的吗？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Tue Dec 04 12:44:20 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2018-12-09 Youngsing

    学习了，嘻嘻，谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=964008, encodeId=3efd9640082b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=彧日东升, createdTime=Sun May 09 16:54:32 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355407, encodeId=4e2d35540e08, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Fri Dec 14 18:46:09 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354960, encodeId=712c35496094, content=学习了，嘻嘻，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/07/f34da8a238e598ec20667d5040f7d424.jpg, createdBy=ae7e2163267, createdName=Youngsing, createdTime=Sun Dec 09 22:18:30 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354498, encodeId=24b135449808, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Wed Dec 05 08:16:56 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354426, encodeId=b8e63544262b, content=有翻译版的吗？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Tue Dec 04 12:44:20 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2018-12-05 衣带渐宽

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=964008, encodeId=3efd9640082b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=彧日东升, createdTime=Sun May 09 16:54:32 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355407, encodeId=4e2d35540e08, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Fri Dec 14 18:46:09 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354960, encodeId=712c35496094, content=学习了，嘻嘻，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/07/f34da8a238e598ec20667d5040f7d424.jpg, createdBy=ae7e2163267, createdName=Youngsing, createdTime=Sun Dec 09 22:18:30 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354498, encodeId=24b135449808, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Wed Dec 05 08:16:56 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354426, encodeId=b8e63544262b, content=有翻译版的吗？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7e72490279, createdName=12478b7dm11(暂无昵称), createdTime=Tue Dec 04 12:44:20 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2018-12-04 12478b7dm11(暂无昵称)

    有翻译版的吗？

    0

相关指南

2018 ADA立场声明：青年起病的2型糖尿病的评估和管理

美国糖尿病学会(ADA,American Diabetes Association) · 2018-11-13

2018 ADA/EASD共识：2型糖尿病患者高血糖的管理

美国糖尿病学会(ADA,American Diabetes Association) · 2018-10-04

2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读

暂未更新 · 2018-05-15

2型糖尿病起始胰岛素后方案转换的临床指导建议

中国内分泌相关专家小组（统称） · 2018-02-20

社区医生2型糖尿病管理流程与分级诊疗规范（深圳专家共识）

中国内分泌相关专家小组（统称） · 2018-03-30

2017 RSSDI临床实践建议：2型糖尿病的管理

印度糖尿病研究学会(RSSDI,Research Society for the Study of Diabetes in India) · 2018-03-10

Baidu
map
Baidu
map
Baidu
map